Antidiuretic Hormone Receptor Antagonists

Endogenous compounds and drugs that inhibit or block the activity of ANTIDUIRETIC HORMONE RECEPTORS.

Also Known As:

Antidiuretic Hormone Antagonists; Vasopressin Antagonists; Vasopressin Receptor Antagonists; Antagonist, Antidiuretic Hormone; Antagonist, Vasopressin; Antagonist, Vasopressin Receptor; Antagonists, Antidiuretic Hormone; Antagonists, Vasopressin; Antagonists, Vasopressin Receptor; Hormone Antagonist, Antidiuretic; Hormone Antagonists, Antidiuretic; Receptor Antagonist, Vasopressin; Receptor Antagonists, Vasopressin; Antidiuretic Hormone Antagonist; Antidiuretic Hormone Receptor Antagonist; Vasopressin Antagonist; Vasopressin Receptor Antagonist

Networked: 343 relevant articles (29 outcomes, 58 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Molecular Mechanisms of Pharmacological Action: 24
    - Antidiuretic Hormone Receptor Antagonists: 343
  - Physiological Effects of Drugs: 1
    - Natriuretic Agents: 476
      - Antidiuretic Hormone Receptor Antagonists: 343

Experts

1.	Gheorghiade, Mihai: 19 articles (01/2015 - 07/2003)
2.	Orlandi, Cesare: 10 articles (01/2012 - 04/2004)
3.	Ouyang, John: 9 articles (04/2012 - 04/2004)
4.	Goldsmith, Steven R: 7 articles (02/2021 - 06/2006)
5.	Schrier, Robert W: 7 articles (10/2013 - 04/2006)
6.	Torres, Vicente E: 6 articles (04/2015 - 11/2005)
7.	Udelson, James E: 4 articles (02/2021 - 12/2005)
8.	Hoorn, Ewout J: 4 articles (01/2019 - 01/2008)
9.	Decaux, Guy: 4 articles (02/2015 - 04/2003)
10.	Greenberg, Arthur: 4 articles (10/2013 - 06/2008)

Related Diseases

1.	Hyponatremia 09/01/2011 - "Clinical trials have demonstrated that vasopressin receptor antagonists (VRAs) are effective in treating hypervolemic hyponatremia in ADHF without a negative impact on renal function. " 08/01/2010 - "Vasopressin antagonists are effective for the treatment of hypervolemic and euvolemic hyponatremia." 11/01/2007 - "Vasopressin receptor antagonists have been shown to be safe and effective in clinical trials in patients with hyponatremia." 11/01/2010 - "In this article, we discuss the mechanisms of hyponatremia in ADHF, review its evolving prognostic significance, and evaluate the efficacy of various treatments for hyponatremia, including the recently approved vasopressin receptor antagonists for managing hyponatremia among patients hospitalized for ADHF." 12/01/2011 - "Initial studies with vasopressin antagonists showed promise in their ability to increase urine output, provide short-term symptom relief, and correct hyponatremia while maintaining renal function. "
2.	Heart Failure 05/01/2008 - "Based on data from available clinical trials, vasopressin antagonists may offer a new treatment option for patients with congestive heart failure. " 02/01/2015 - "Vasopressin receptor antagonists for the treatment of heart failure: a systematic review and meta-analysis of randomized controlled trials." 03/01/2005 - "The following is a review of current experimental and clinical studies using vasopressin antagonists and their potential role in the treatment of heart failure." 08/01/2017 - "Vasopressin receptor antagonists in patients with chronic heart failure." 02/01/2015 - "We aimed to assess benefits and harms of vasopressin receptor antagonists (VRAs) versus placebo in addition to standard care in adults with heart failure (HF). "
3.	Fibrosis (Cirrhosis) 01/01/2003 - "Clinical need for antidiuretic hormone antagonists in cirrhosis." 03/21/2015 - "In this review, we discuss the pathophysiology and various treatment modalities, including selective vasopressin receptor antagonists, for the management of hyponatremia in patients with cirrhosis. " 10/01/2007 - "The development of nonpeptide vasopressin receptor antagonists (VRAs) offers prospects for the treatment of euvolaemic (SI ADH) or hypervolaemic hyponatraemia (congestive heart failure or cirrhosis). " 04/01/2003 - "Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial." 04/01/2003 - "An orally active vasopressin receptor antagonist can correct hyponatremia in patients with cirrhosis and ascites. "
4.	Autosomal Dominant Polycystic Kidney (ADPKD) 02/01/2011 - "On cross-sectional analysis, copeptin is associated with disease severity in ADPKD patients, supporting the results of experimental studies that suggest that vasopressin antagonists have a renoprotective effect in ADPKD and offering a good prospect for clinical studies with these agents." 07/01/2022 - "Patients with autosomal dominant polycystic kidney disease (ADPKD) may require specific therapy with vasopressin receptor antagonists to slow the progression of renal disease. " 01/15/2014 - "Vasopressin antagonists show for the first time a beneficial effect on ADPKD cyst growth and renal function in a large cohort of patients. " 06/01/2013 - "inhibitors of V2 vasopressin antagonists) may have in ADPKD positive impact not only of the growth of the cysts and kidney volume, but also on the rate of loss of glomerular filtration rate. " 04/01/2015 - "Several drugs designed to slow or arrest the progression of ADPKD have shown promise in preclinical models and clinical trials, including vasopressin receptor antagonists and somatostatin analogs. "
5.	Ascites 01/01/2014 - "Vaptans, nonpeptide vasopressin receptor antagonists, may also reduce hyponatraemia and ascites, even if the clinical effects in HRS remain unknown. " 08/01/2010 - "Vasopressin receptor antagonists, by increasing free water clearance, may reduce the recurrence of ascites. " 11/01/2015 - "We examined this question using data from three randomized trials of satavaptan, a vasopressin receptor antagonist that does not affect HE risk, in cirrhotic patients with ascites. " 05/01/2011 - "Satavaptan (a vasopressin receptor antagonist) was investigated for treatment of refractory ascites and appeared to be effective, but this compound is not currently approved by the US Food and Drug Administration (FDA). " 07/01/2008 - "Vasopressin receptor antagonists improve serum sodium concentration by increasing renal solute-free water excretion, but their effects on the management of ascites have not been assessed. "

Related Drugs and Biologics

1.	Tolvaptan
2.	Vasopressins (Vasopressin)
3.	Sodium
4.	Diuretics
5.	Somatostatin (Somatotropin Release-Inhibiting Factor)
6.	Cytokines
7.	Endothelin Receptor Antagonists
8.	Natriuretic Peptides
9.	Hemoglobins (Hemoglobin)
10.	Creatinine

Related Therapies and Procedures

1.	Cardiac Resynchronization Therapy
2.	Neurological Rehabilitation
3.	Therapeutics
4.	Drug Therapy (Chemotherapy)
5.	Cardiomyoplasty